7
Jul 2026
Beckman Coulter Diagnostics expands Alzheimer’s portfolio with CE-marked p-Tau217 blood test and new high-specificity research assay
Beckman Coulter Diagnostics, a global leader in clinical diagnostics and a Danaher company, today announced it received CE Mark under IVDR for its Access p-Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline.